HARROW, INC.
HROWNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $272.3M | $199.6M | $130.2M | $88.6M | $72.5M | $48.9M |
| Operating income | $30.5M | $8.8M | $431,000 | $1.9M | $1.6M | $385,000 |
| Net income | −$5.1M | −$17.5M | −$24.4M | −$14.1M | −$18.0M | −$3.4M |
| Total assets | $399.5M | $389.0M | $312.2M | $157.4M | $98.3M | $57.5M |
| Total liabilities | $347.4M | $319.7M | $241.8M | $130.1M | $87.4M | $30.6M |
| Equity | $52.4M | $69.7M | $70.8M | $27.6M | $11.3M | $27.2M |
| EPS (diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 |
| Shares out. | 35.7M | 35.4M | 30.0M | 27.0M | 26.0M | 25.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 11.2%
- Net margin
- −1.9%
- Return on equity
- −9.8%
- Return on assets
- −1.3%
- Return on capital (ROCE)
- 10.1%
- Liabilities / assets
- 87.0%
- Debt / equity
- 6.62×
- Book value / share
- $1.47
- Revenue growth (YoY)
- 36.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 1.29grey zone
- Accruals / assets
- −12.3%clean
- Beneish M-Score
- -3.05normal
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 4 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Altman Z″ in the grey zone
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 17, 2025
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2011
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Opaleye Management Inc.Passive (13G)May 11, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Kaufman Daniel LouisPassive (13G)Mar 11, 2026
- Baum Mark LActivist (13D)Apr 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6.5M | 5.2 | +0.3% |
| Apr 30, 2026 | 6.5M | 11.8 | +1.1% |
| Apr 15, 2026 | 6.4M | 16.6 | -6.6% |
| Mar 31, 2026 | 6.9M | 11.2 | +9.8% |
| Mar 13, 2026 | 6.2M | 3.9 | +16.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 11, 2026
- Entered a material agreement · New financial obligation · Other material eventMar 27, 2026
- Other material eventMar 24, 2026
- Other material eventMar 24, 2026
- Regulation FD disclosureMar 10, 2026
- Results of operations · Regulation FD disclosureMar 2, 2026
- Results of operations · Director / officer changeFeb 2, 2026
- Completed an acquisition or disposition · Unregistered equity sale · Other material eventNov 18, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4May 19, 2026
- 4May 19, 2026
- 4May 18, 2026
- 4May 15, 2026
- 4May 15, 2026
- 10-QMay 11, 2026
- SCHEDULE 13G/AMay 11, 2026
- 8-KMay 11, 2026
- DEFA14AApr 24, 2026
- DEF 14AApr 24, 2026
- 8-KMar 27, 2026
- SCHEDULE 13G/AMar 27, 2026
- 8-KMar 24, 2026
- 8-KMar 24, 2026
- SCHEDULE 13GMar 11, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.